1. Scrip
  2. >>New Products

Vertex New CF Combo Addresses More Patients, With Daily Dosing

 
• By Joseph Haas

Vertex hopes to convert CF patients to new combo Alyftrek from Trikafta with once-daily dosing. Approved on 20 December, the new triplet has longer patent protection and 7% higher US pricing.

Vertex HQ, Boston
Vertex obtained US FDA approval for new CF combo product Alyftrek

Vertex is extending its lead in the cystic fibrosis space and setting a premium price for its next-generation triple-combination product Alyftrek (vanzacaftor/tezacaftor/deutivacaftor), which it intends to gradually replace its blockbuster Trikafta (elexacaftor/tezacaftor/ivacaftor). The Boston-based company set a wholesale acquisition cost (WAC) of $370,269 a year for Alyftrek, roughly a 7% premium over Trikafta’s US pricing.

Key Takeaways
  • Vertex obtained US FDA approval for Alyftrek, a triplet therapy for cystic fibrosis that it hopes to switch patients to from Trikafta.

The 20 December US Food and Drug Administration approval gave Vertex some good news on the heels of a clinical development setback for its non-opioid pain candidate suzetrigine (VX-548), which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

Pipeline Watch: Eight Approvals And Nine Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Therapy Areas

ASCO: Lupin Presents Early Data On PRMT5 Inhibitor

 
• By Vibha Ravi

ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

 
• By Joseph Haas

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.

ASCO: IO Continues Climb To Earlier Use With AstraZeneca’s MATTERHORN, BMS’s NIVOPOSTOP

 
• By Mary Jo Laffler

Data presented at ASCO supports use of AZ’s Imfinzi for perioperative gastric cancer and BMS’s Opdivo for adjuvant treatment of head and neck cancer.